Kaplitt M G, Leone P, Samulski R J, Xiao X, Pfaff D W, O'Malley K L, During M J
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520-8039.
Nat Genet. 1994 Oct;8(2):148-54. doi: 10.1038/ng1094-148.
Adeno-associated viral (AAV) vectors are non-pathogenic, integrating DNA vectors in which all viral genes are removed and helper virus is completely eliminated. To evaluate this system in the post-mitotic cells of the brain, we found that an AAV vector containing the lacZ gene (AAVlac) resulted in expression of beta-galactosidase up to three months post-injection in vivo. A second vector expressing human tyrosine hydroxylase (AAVth) was injected into the denervated striatum of unilateral 6-hydroxydopamine-lesioned rats. Tyrosine hydroxylase (TH) immunoreactivity was detectable in striatal neurons and glia for up to four months and we also found significant behavioural recovery in lesioned rats treated with AAVth versus AAVlac controls. Safe and stable TH gene transfer into the denervated striatum may have potential for the genetic therapy of Parkinson's disease.
腺相关病毒(AAV)载体是无致病性的整合型DNA载体,其中所有病毒基因均被去除,辅助病毒也被完全清除。为了在大脑的有丝分裂后细胞中评估该系统,我们发现携带lacZ基因的AAV载体(AAVlac)在体内注射后长达三个月都能导致β-半乳糖苷酶的表达。将表达人酪氨酸羟化酶的第二个载体(AAVth)注射到单侧6-羟基多巴胺损伤大鼠的失神经纹状体中。在纹状体神经元和胶质细胞中,酪氨酸羟化酶(TH)免疫反应性在长达四个月的时间内都可检测到,并且我们还发现,与AAVlac对照组相比,接受AAVth治疗的损伤大鼠有明显的行为恢复。将安全稳定的TH基因转移到失神经纹状体中可能对帕金森病的基因治疗具有潜力。